JUN 06, 2017 01:24 PM PDT

Protecting Beta Cells to Treat Type 1 Diabetes

WRITTEN BY: Kara Marker

A new way to treat - and maybe prevent - type 1 diabetes revolves around protecting beta cells, the cells produced by the pancreas to make insulin. Jackson Laboratory researchers conducted a new study published in the Journal of Immunology focused on finding the best way to provide this protection.

Human-stem-cell-derived beta cells that have formed islet-like clusters in a mouse. Credit: Harvard Magazine

The pancreas produces beta cells to make insulin, which in turn transports glucose to bring energy to cells all over the body. Beta cells are the primary target of autoreactive T cells activated by B cells during the development of type 1 diabetes (T1D), which is why people with this condition have to receive insulin injections.

When beta cells damaged by autoreactive T cells can’t produce insulin to carry glucose like normal, glucose builds up in the blood, nerves, and blood vessels, and organs damage characteristic of T1D results. For their anti-T1D approach, Jackson Laboratory researchers are going straight to the source: B cells.

“If you can target those antigen-presenting B-cells, that could be potentially a very effective disease intervention," said lead author David Serreze, PhD. "Our approach targets an appropriate population of the B cells among the white blood cells, resulting in inactivation of the cascade of autoimmunity against the insulin-producing pancreatic beta cells, and hence subsequently blocking diabetes development."

While targeting the B cells that ultimately activate autoreactive T cells would protect insulin-producing beta cells, there are other B cells that provide healthy actions that scientists wouldn’t want squandered. An ideal approach would be to block the B cells that activate autoreactive T cells without destroying the healthy B cells that activate healthy T cell responses to invading pathogens.

Serreze’s study applied a gene manipulation approach to find the right target for the right B cells. They used non-obese diabetic mice treated with a B cell pathway inhibitor called AID/RAD51. The mice treated with this inhibitor had larger populations of B cells that suppressed autoreactive T cell responses instead of activating them, a result that also greatly reduced T1D development compared to mice who only received a placebo.

"To combat T1D, we're taking out this whole pathway to block autoreactive cells. But on the flip side, you may want to keep this pathway active if you want to keep antitumor immune responses in place,” Serreze explained. “Ultimately, this approach could potentially be applicable to any autoimmune disease that has a B-cell component."

Source: Jackson Laboratory

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
SEP 17, 2019
Immunology
SEP 17, 2019
Heating Up on the Flu
Climate change may affect the future of vaccinations and nutrition....
SEP 17, 2019
Health & Medicine
SEP 17, 2019
Can a Low-Carb Diet Treat Osteoarthritis?
A pilot study suggests it might. Researchers at the University of Alabama, Birmingham, found that a low-carbohydrate diet was able to reduce pain intensity...
SEP 17, 2019
Microbiology
SEP 17, 2019
Malaria Vaccine Program Begins in Malawi
Malaria sickens around 200 million people every year, killing around 435,000. Children are most vulnerable. A vaccine aims to change that....
SEP 17, 2019
Health & Medicine
SEP 17, 2019
Siblings lead Researchers to Discover New Immunodeficiency Disease
An infant was suffering from inflammatory bowel disease, eczema, food allergies, lung disease, and persistent cytomegalovirus (CMV) infection. His older si...
SEP 17, 2019
Health & Medicine
SEP 17, 2019
Why does the flu virus thrive during winter?
If you’re one of the nearly 7 million people who suffered from influenza last season, you might be curious why the virus hits so much during winter m...
SEP 17, 2019
Genetics & Genomics
SEP 17, 2019
DNA Construction Kit Could Drive Down Costs of Immune Therapy
Researchers at KU Leuven in Belgium have created a DNA construction kit that, when injected into muscle cells, enables sheep to produce new antibodies to f...
Loading Comments...